2620 related articles for article (PubMed ID: 16827106)
61. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
62. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen.
Maraqa L; Cummings M; Peter MB; Shaaban AM; Horgan K; Hanby AM; Speirs V
Clin Cancer Res; 2008 Jan; 14(2):405-11. PubMed ID: 18223215
[TBL] [Abstract][Full Text] [Related]
63. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
Kurebayashi J; Nukatsuka M; Sonoo H; Uchida J; Kiniwa M
Cancer Chemother Pharmacol; 2010 Jan; 65(2):219-25. PubMed ID: 19455332
[TBL] [Abstract][Full Text] [Related]
64. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
Saji S; Kawakami M; Hayashi S; Yoshida N; Hirose M; Horiguchi S; Itoh A; Funata N; Schreiber SL; Yoshida M; Toi M
Oncogene; 2005 Jun; 24(28):4531-9. PubMed ID: 15806142
[TBL] [Abstract][Full Text] [Related]
65. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
[TBL] [Abstract][Full Text] [Related]
66. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
[TBL] [Abstract][Full Text] [Related]
67. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer.
Roberts CG; Millar EK; O'Toole SA; McNeil CM; Lehrbach GM; Pinese M; Tobelmann P; McCloy RA; Musgrove EA; Sutherland RL; Butt AJ
Oncogene; 2011 Jul; 30(28):3186-97. PubMed ID: 21383694
[TBL] [Abstract][Full Text] [Related]
68. Aromatase induction in tamoxifen-resistant breast cancer: Role of phosphoinositide 3-kinase-dependent CREB activation.
Phuong NT; Lim SC; Kim YM; Kang KW
Cancer Lett; 2014 Aug; 351(1):91-9. PubMed ID: 24836190
[TBL] [Abstract][Full Text] [Related]
69. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
Liu H; Zhang HW; Sun XF; Guo XH; He YN; Cui SD; Fan QX
Chin Med J (Engl); 2013 Aug; 126(16):3030-4. PubMed ID: 23981606
[TBL] [Abstract][Full Text] [Related]
70. Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways.
Wang LJ; Han SX; Bai E; Zhou X; Li M; Jing GH; Zhao J; Yang AG; Zhu Q
Oncol Rep; 2013 Apr; 29(4):1563-9. PubMed ID: 23338782
[TBL] [Abstract][Full Text] [Related]
71. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
72. Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen.
Liu H; Lu S; Gu L; Gao Y; Wang T; Zhao J; Rao J; Chen J; Hao X; Tang SC
Cell Physiol Biochem; 2014; 33(2):365-74. PubMed ID: 24557447
[TBL] [Abstract][Full Text] [Related]
73. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
74. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
75. Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents.
Liu S; Kulp SK; Sugimoto Y; Jiang J; Chang HL; Lin YC
Breast Cancer Res Treat; 2002 Jan; 71(1):21-35. PubMed ID: 11859871
[TBL] [Abstract][Full Text] [Related]
76. Re-expression of estrogen receptor alpha using a tetracycline-regulated gene expression system induced estrogen-mediated growth inhibition of the MDA-MB-231 breast cancer cell line.
Barrón-González A; Castro Romero I
Biochem Cell Biol; 2004 Apr; 82(2):335-42. PubMed ID: 15060629
[TBL] [Abstract][Full Text] [Related]
77. In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen.
Chen JL; Chang CJ; Wang JY; Wen CS; Tseng LM; Chang WC; Noomhorm N; Liu HJ; Chen WS; Chiu JH; Shyr YM
Integr Cancer Ther; 2014 May; 13(3):226-39. PubMed ID: 24525674
[TBL] [Abstract][Full Text] [Related]
78. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation.
Jeng MH; Parker CJ; Jordan VC
Cancer Res; 1992 Dec; 52(23):6539-46. PubMed ID: 1423300
[TBL] [Abstract][Full Text] [Related]
79. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
80. [Effects of antiestrogens and medroxyprogesterone acetate on the clonogenic growth of tamoxifen-sensitive and resistant human breast cancer cells].
Nomura Y; Tashiro H; Takaeko F
Gan To Kagaku Ryoho; 1985 Apr; 12(4):844-50. PubMed ID: 3157351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
